Enzyme Modification Stalls Resistant Tumor Growth
St. Jude researchers link a METTL13-driven protein change to KRAS-inhibitor-resistant tumors, a finding that remains in pre-clinical research.
Tennessee Life Sciences News
St. Jude researchers link a METTL13-driven protein change to KRAS-inhibitor-resistant tumors, a finding that remains in pre-clinical research.